CN109890404A - 视觉功能再生剂或视觉功能降低预防剂 - Google Patents

视觉功能再生剂或视觉功能降低预防剂 Download PDF

Info

Publication number
CN109890404A
CN109890404A CN201780066838.2A CN201780066838A CN109890404A CN 109890404 A CN109890404 A CN 109890404A CN 201780066838 A CN201780066838 A CN 201780066838A CN 109890404 A CN109890404 A CN 109890404A
Authority
CN
China
Prior art keywords
amino acid
visual performance
ala
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780066838.2A
Other languages
English (en)
Chinese (zh)
Inventor
栗原俊英
坚田侑作
国见洋光
坪田一男
神取秀树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio University
Nagoya Institute of Technology NUC
Original Assignee
Keio University
Nagoya Institute of Technology NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University, Nagoya Institute of Technology NUC filed Critical Keio University
Priority to CN202311592678.9A priority Critical patent/CN117695375A/zh
Priority to CN202311592670.2A priority patent/CN117701604A/zh
Priority to CN202311593358.5A priority patent/CN117701637A/zh
Priority to CN202311592868.0A priority patent/CN117701605A/zh
Publication of CN109890404A publication Critical patent/CN109890404A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780066838.2A 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂 Pending CN109890404A (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202311592678.9A CN117695375A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311592670.2A CN117701604A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311593358.5A CN117701637A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311592868.0A CN117701605A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-172149 2016-09-02
JP2016172149 2016-09-02
PCT/JP2017/031579 WO2018043707A1 (ja) 2016-09-02 2017-09-01 視覚機能再生剤又は視覚機能低下予防剤

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN202311592868.0A Division CN117701605A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311592670.2A Division CN117701604A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311592678.9A Division CN117695375A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311593358.5A Division CN117701637A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂

Publications (1)

Publication Number Publication Date
CN109890404A true CN109890404A (zh) 2019-06-14

Family

ID=61301215

Family Applications (5)

Application Number Title Priority Date Filing Date
CN202311592678.9A Pending CN117695375A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311592670.2A Pending CN117701604A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311592868.0A Pending CN117701605A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN201780066838.2A Pending CN109890404A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311593358.5A Pending CN117701637A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN202311592678.9A Pending CN117695375A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311592670.2A Pending CN117701604A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂
CN202311592868.0A Pending CN117701605A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311593358.5A Pending CN117701637A (zh) 2016-09-02 2017-09-01 视觉功能再生剂或视觉功能降低预防剂

Country Status (6)

Country Link
US (2) US11932679B2 (enExample)
EP (2) EP4653537A2 (enExample)
JP (4) JP6757024B2 (enExample)
CN (5) CN117695375A (enExample)
CA (1) CA3035651A1 (enExample)
WO (1) WO2018043707A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024199431A1 (zh) * 2023-03-29 2024-10-03 郑州大学第一附属医院 一种嵌合蛋白在治疗视神经变性疾病中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117695375A (zh) 2016-09-02 2024-03-15 学校法人庆应义塾 视觉功能再生剂或视觉功能降低预防剂
CA3127535A1 (en) * 2019-01-18 2020-07-23 Restore Vision Inc. Preventing, and suppressing progression of, retinal disease, improving visual cognitive behavioral function, and strengthening visual function
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
CA3154358A1 (en) * 2019-09-13 2021-03-18 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
JPWO2022059736A1 (enExample) * 2020-09-17 2022-03-24

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138616A1 (en) * 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
EP3437473A1 (en) 2006-05-04 2019-02-06 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
KR101197129B1 (ko) 2009-09-14 2012-11-07 서강대학교산학협력단 글레오박터 로돕신 및 ａｔｐ 합성효소가 방향성을 갖도록 장착된 ａｔｐ 합성용 조성물
CA2791094A1 (en) 2010-03-17 2011-09-22 The Board Of Trustees Of The Leland Stanford Junior University Light-sensitive ion-passing molecules
KR101061482B1 (ko) 2010-04-20 2011-09-02 서강대학교산학협력단 카로테노이드가 재구성된 글레오박터 로돕신
WO2012061676A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
JP6483083B2 (ja) * 2013-03-14 2019-03-13 ウェイン ステイト ユニバーシティー 治療用化合物の眼への送達を増強する方法
CN117695375A (zh) 2016-09-02 2024-03-15 学校法人庆应义塾 视觉功能再生剂或视觉功能降低预防剂
CA3127535A1 (en) 2019-01-18 2020-07-23 Restore Vision Inc. Preventing, and suppressing progression of, retinal disease, improving visual cognitive behavioral function, and strengthening visual function
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
CA3154358A1 (en) 2019-09-13 2021-03-18 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138616A1 (en) * 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KENGO SASAKI等: "Chimeric Proton-Pumping Rhodopsins Containing the Cytoplasmic Loop of Bovine Rhodopsin", 《PLOS ONE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024199431A1 (zh) * 2023-03-29 2024-10-03 郑州大学第一附属医院 一种嵌合蛋白在治疗视神经变性疾病中的应用

Also Published As

Publication number Publication date
US20240247049A1 (en) 2024-07-25
CN117701637A (zh) 2024-03-15
CN117695375A (zh) 2024-03-15
CN117701605A (zh) 2024-03-15
EP3508212B1 (en) 2025-10-22
CN117701604A (zh) 2024-03-15
US11932679B2 (en) 2024-03-19
WO2018043707A1 (ja) 2018-03-08
JP2020117513A (ja) 2020-08-06
JP7427208B2 (ja) 2024-02-05
US20190194294A1 (en) 2019-06-27
CA3035651A1 (en) 2018-03-08
JP2022126804A (ja) 2022-08-30
JP2024026791A (ja) 2024-02-28
EP3508212A1 (en) 2019-07-10
JP6757024B2 (ja) 2020-09-16
JPWO2018043707A1 (ja) 2019-07-25
EP3508212A4 (en) 2020-05-20
EP4653537A2 (en) 2025-11-26

Similar Documents

Publication Publication Date Title
US20240247049A1 (en) Agent for restoring visual function or agent for preventing deterioration in visual function
US8754048B2 (en) Light-receiving channel rhodopsin having improved expression efficiency
AU2014227600B2 (en) Optogenetic control of behavioral state
AU2017256910B2 (en) Optogenetic visual restoration using Chrimson
US20220402994A1 (en) Nucleic acid construct that encodes chimeric rhodopsin
US20220025018A1 (en) Preventing, and suppressing progression of, retinal disease, improving visual cognitive behavioral function, and strengthening visual function
Li et al. Administration of a mutated myostatin propeptide to neonatal mice significantly enhances skeletal muscle growth
US11771741B2 (en) Nucleic acid construct that encodes chimeric rhodopsin
EP3191508B1 (en) Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays
CN115335525B (zh) 经修饰的通道视紫红质
US20250109199A1 (en) Compositions and methods for vldlr-based decoy receptors against alphaviruses
JP7142369B2 (ja) 哺乳動物細胞に対する外来遺伝子の導入効率の向上剤
CN117795080A (zh) 利用snare的核酸构建体
HK40074775A (en) Nucleic acid construct that encodes chimeric rhodopsin
Rather Identification, characterization and expression profiling of kisspeptin gene in Catla catla (Hamilton, 1822)
HK1234077A1 (en) Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays
HK1234077B (en) Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination